{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:10:41Z","timestamp":1780474241832,"version":"3.54.1"},"reference-count":27,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Santen SA","award":["19-0726"],"award-info":[{"award-number":["19-0726"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: To investigate the non-inferiority of preservative-free (PF) tafluprost eye drops (Taflotan sine\u00ae) compared to latanoprost eye drops (Xalatan\u00ae) in reducing mean 24 h intraocular pressure (IOP) on the second day of a diurnal IOP measurement. Methods: In this retrospective monocentric cohort study, patients suffering from primary open-angle glaucoma, ocular hypertension, normal tension glaucoma, pigment dispersion glaucoma, or pseudoexfoliation glaucoma who had undergone inpatient diurnal IOP measurement were included. Patients of cohort 1 used latanoprost eye drops as monotherapy; patients of cohort 2 used preservative-free tafluprost eye drops. Data from 7 January 2005 to 9 July 2019, inclusive, were analyzed. Results: Ninety-three eyes were included (n = 59 latanoprost group, n = 34 PF tafluprost group). Mean 24 h IOP on day 2 was 14.1 mmHg (SD 2.3) in the latanoprost group and 14.5 mmHg (SD 3.4) in the PF tafluprost group. The non-inferiority of PF tafluprost eye drops to latanoprost eye drops in efficacy on mean 24 h IOP could not be confirmed (95% CI \u22121.5, \u221e, p = 0.235). The average difference in mean IOP at the individual measurement times between both cohorts was 0.24 mmHg (SD 0.17) on day 1 and 0.44 mmHg (SD 0.6) on day 2. The non-inferiority of PF tafluprost compared to latanoprost regarding fluctuation range could not be demonstrated for both days. Conclusions: The data suggests slight inferiority of PF tafluprost to latanoprost eye drops. There were similar mean 24 h IOP values in both cohorts. PF tafluprost eye drops remain a useful treatment option as long as the patient\u2019s individual target pressure is achieved. Furthermore, according to the literature, it is also a treatment option for patients with symptoms of ocular surface disease and other side effects affecting the ocular surface while receiving preservative-containing topical therapy.<\/jats:p>","DOI":"10.3390\/jcm14248932","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:53:46Z","timestamp":1765986826000},"page":"8932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Circadian Efficacy of Tafluprost Eye Drops (Taflotan Sine\u00ae) with Latanoprost Eye Drops (Xalatan\u00ae) in the Treatment of Open-Angle Glaucoma and Ocular Hypertension"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-3819","authenticated-orcid":false,"given":"Anna","family":"Beck","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Theresa","family":"Rauschkolb-Olk","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Welzel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wolfrum","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7572-4749","authenticated-orcid":false,"given":"Christina","family":"Korb","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-6752","authenticated-orcid":false,"given":"Irene","family":"Schmidtmann","sequence":"additional","affiliation":[{"name":"Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6273-3684","authenticated-orcid":false,"given":"Elsa Wilma","family":"Boehm","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-7396","authenticated-orcid":false,"given":"Katrin","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"#cr-split#-ref_1.1","unstructured":"(2021). GBD 2019 Blindness and Vision Impairment Collaborators"},{"key":"#cr-split#-ref_1.2","unstructured":"Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health, 9, e144-e160."},{"key":"ref_2","first-page":"225","article-title":"The Diagnosis and Treatment of Glaucoma","volume":"117","author":"Schuster","year":"2020","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.survophthal.2019.09.004","article-title":"Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma","volume":"65","author":"Mansouri","year":"2020","journal-title":"Surv. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s12325-018-0812-z","article-title":"Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment","volume":"35","author":"Konstas","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(2017). European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition\u2014Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br. J. Ophthalmol., 101, 130\u2013195.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1007\/s10792-021-01947-2","article-title":"Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension","volume":"41","author":"Muz","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14740338.2021.1873947","article-title":"The treatment of glaucoma using topical preservative-free agents: An evaluation of safety and tolerability","volume":"20","author":"Konstas","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","article-title":"Ocular benzalkonium chloride exposure: Problems and solutions","volume":"36","author":"Goldstein","year":"2022","journal-title":"Eye"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40265-017-0843-9","article-title":"Preservative-Free Prostaglandin Analogs and Prostaglandin\/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages","volume":"78","author":"Katsanos","year":"2018","journal-title":"Drugs"},{"key":"ref_11","first-page":"103","article-title":"Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma","volume":"6","author":"Grybauskiene","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"804730","DOI":"10.1100\/2012\/804730","article-title":"A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients","volume":"2012","author":"Ranno","year":"2012","journal-title":"Sci. World J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/bjophthalmol-2012-303026","article-title":"Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension","volume":"97","author":"Konstas","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3540749","DOI":"10.1155\/2017\/3540749","article-title":"Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost","volume":"2017","author":"Tokuda","year":"2017","journal-title":"J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kim, J.M., Park, S.W., Seong, M., Ha, S.J., Lee, J.W., Rho, S., Lee, C.E., Kim, K.N., Kim, T.W., and Sung, K.R. (2021). Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060501"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Park, S.W., Lee, J., and Kook, M.S. (2022). Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide\/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020201"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.4103\/ijo.IJO_165_21","article-title":"Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma","volume":"69","author":"Hagras","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12325-016-0448-9","article-title":"24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide\/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy","volume":"34","author":"Konstas","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/112067210701700108","article-title":"A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%\/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension","volume":"17","author":"Hommer","year":"2007","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ceo.14028","article-title":"The surgical management of glaucoma: A review","volume":"50","author":"Lim","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/jop.2011.0081","article-title":"Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma","volume":"28","author":"Konstas","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1167\/iovs.08-2889","article-title":"The circadian curve of intraocular pressure: Can we estimate its characteristics during office hours?","volume":"50","author":"Fogagnolo","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.survophthal.2009.05.001","article-title":"Understanding the importance of IOP variables in glaucoma: A systematic review","volume":"54","author":"Sultan","year":"2009","journal-title":"Surv. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12325-016-0302-0","article-title":"24-h Efficacy of Glaucoma Treatment Options","volume":"33","author":"Konstas","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_26","first-page":"623","article-title":"Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost","volume":"5","author":"Hommer","year":"2011","journal-title":"Clin. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:05:07Z","timestamp":1765987507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":27,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248932"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248932","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}